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Clinical validation of a multiplex
PCR‑based detection assay using
saliva or nasopharyngeal samples
for SARS‑Cov‑2, influenza A and B
Nikhil S. Sahajpal1, Ashis K. Mondal1, Sudha Ananth1, Allan Njau2, Kimya Jones1,
Pankaj Ahluwalia1, Eesha Oza1, Ted M. Ross3, Vamsi Kota4, Arvind Kothandaraman6,
Sadanand Fulzele5, Madhuri Hegde6, Alka Chaubey1,7, Amyn M. Rojiani8 & Ravindra Kolhe1*
The COVID-19 pandemic has resulted in significant diversion of human and material resources to
COVID-19 diagnostics, to the extent that influenza viruses and co-infection in COVID-19 patients
remains undocumented and pose serious public-health consequences. We optimized and validated
a highly sensitive RT-PCR based multiplex-assay for the detection of SARS-CoV-2, influenza A and
B viruses in a single-test. This study evaluated clinical specimens (n = 1411), 1019 saliva and 392
nasopharyngeal swab (NPS), tested using two-assays: FDA-EUA approved SARS-CoV-2 assay that
targets N and ORF1ab gene, and the PKamp-RT-PCR based assay that targets SARS-CoV-2, influenza
viruses A and B. Of the 1019 saliva samples, 17.0% (174/1019) tested positive for SARS-CoV-2 using
either assay. The detection rate for SARS-CoV-2 was higher with the multiplex assay compared to
SARS-specific assay [91.9% (160/174) vs. 87.9% (153/174)], respectively. Of the 392 NPS samples,
10.4% (41/392) tested positive for SARS-CoV-2 using either assay. The detection rate for SARS-CoV-2
was higher with the multiplex assay compared to SARS-specific assay [97.5% (40/41) vs. 92.1%
(39/41)], respectively. This study presents clinical validation of a multiplex-PCR assay for testing SARSCoV-2, influenza A and B viruses, using NPS and saliva samples, and demonstrates the feasibility of
implementing the assay without disrupting the existing laboratory workflow.
The outbreak of COVID-19 (caused by SARS-CoV-2) is currently a raging pandemic and has led to major
socio-economic disruption worldwide. Since the identification of SARS-CoV-2 in the region of Wuhan, China,
77,343,652 confirmed cases with over 1,702,293 COVID-19 related deaths have been reported globally (https://
coronavirus.jhu.edu/map.html, last accessed December 21, 2020). In an attempt to curtail the spread of the disease, testing for SARS-CoV-2 has been identified as the single most important measure. Substantial emergency
policy changes as well as state-sponsored funding have facilitated implementation of testing for the virus in the
USA and around the world1,2. However, due to the diversion of personnel, resources, and supplies to SARSCoV-2 testing, the testing of viral pathogens that normally cause seasonal respiratory tract infections has been
marginalized. Acute respiratory tract infections (ARTIs) remain the leading cause of morbidity and mortality
from infectious diseases. The Global Burden of Disease (2017) data has demonstrated that influenza contributed 11.5% of the total lower respiratory tract infections (LRTIs), leading to over 9 million hospitalizations and
145,000 deaths across all age groups in a single calendar year3. Further, co-infection with bacterial, fungal, or
viral pathogens has been associated with disease severity and death in the current pandemic. A report originating
from Wuhan, China, identified that 80% of COVID-19 patients had co-infection with at least one respiratory
pathogen, with the most common being influenza viruses A and B (60% and 53.30% respectively)4. The neglect
of these co-circulating pathogens, especially influenza A and B viruses has generated serious public health gaps

1

Department of Pathology, Medical College of Georgia, Augusta University, BAE 2576, 1120 15th Street, Augusta,
GA 30912, USA. 2Department of Pathology, Aga Khan University Hospital, Nairobi, Kenya. 3Center for Vaccines
and Immunology, University of Georgia, Athens, GA, USA. 4Department of Medicine, Medical College of Georgia,
Augusta University, Augusta, GA, USA. 5Center for Healthy Aging, Medical College of Georgia, Augusta University,
Augusta, GA, USA. 6Global Laboratory Services, Perkin Elmer, Waltham, USA. 7Bionano Genomics Inc., San
Diego, CA, USA. 8Department of Pathology, Penn State College of Medicine, Hershey, PA, USA. *email: rkolhe@
augusta.edu
Scientific Reports |

(2022) 12:3480

| https://doi.org/10.1038/s41598-022-07152-0

1
Vol.:(0123456789)

www.nature.com/scientificreports/

Figure 1.  Schematic overview of sample processing steps for saliva and NPS samples for SARS-specific assay
and the multiplex assay. The two assays differ in the preparation of RT-PCR master mix preparation, and the
entire protocol remains the same.
both at a clinical and epidemiological level. The potential impact of co-circulating respiratory viral pathogens
during the ongoing influenza season is of major concern at both local and international public health levels.
Further, with the COVID-19 vaccination already in use, testing for pathogens, especially the influenza viruses
in addition to SARS-CoV-2, is already becoming the next diagnostic testing emergency.
We must remain cognizant of the fact that the pandemic has caused a significant change in routine clinical
diagnostic laboratories at the level of re-directing workflow, workforce, supplies, and validating new diagnostic
tests5. It is only in the last few months that laboratories have streamlined testing for SARS-CoV-2, and therefore
shifting to a new workflow and implementing new diagnostic tests, would only unsettle the already exhausted
laboratory staff. To address these clinical and technical challenges, we have optimized and validated a highly
sensitive RT-PCR based multiplex assay for the detection of SARS-CoV-2, influenza A and B viruses in a single
test, using the same workflow, instruments, sample types, supplies, and laboratory personnel currently utilized
for SARS-CoV-2 testing (Fig. 1). Additionally, the assay was validated for both nasopharyngeal swab (NPS) and
saliva samples and demonstrated higher sensitivity in detecting SARS-CoV-2 virus compared to the FDA-EUA
comparator assay (SARS-CoV-2 detection only). We contend that this novel multiplex assay can be used to screen
for influenza viruses along with the detection of SARS-CoV-2 and can be readily implemented in laboratories
across the globe, using essentially the same workflow and rapid turnaround time (TAT).

Material and methods

Study site and ethics. This single-center diagnostic study was conducted at Augusta University, GA, USA.
This site is a Clinical Laboratory Improvement Amendments (CLIA) accredited laboratory for high complexity
testing and is one of the main SARS-CoV-2 testing centers in the State of Georgia. The study was conducted
according to the guidelines of the Declaration of Helsinki, and approved by the Institutional Review Board ABIOMEDICAL I (IRB REGISTRATION #00000150), Augusta University. HAC IRB # 611298. Based on the IRB
approval, the need for consent was waived, all PHI was removed and all data was anonymized before accessing
for the study.
Patient specimens and setting. The study evaluated 1411 clinical specimens that included 1019 saliva
and 392 NPS samples collected in either healthcare or community setting, tested using both the FDA-EUA
approved SARS-CoV-2 and the PKamp RT-PCR based assays. As a standard protocol, NPS samples were collected by a healthcare worker using a sterile flocked swab placed in a sterile tube containing the viral transport medium (VTM) (Becton Dickinson, USA, cat no. 22053). The saliva samples were collected under the
supervision of a healthcare worker in Omni tubes (Omni International, USA, SKU: 19-628D) without adding
any media. All samples were stored at 4 °C temperature and transported to the SARS-CoV-2 testing facility at
Augusta University, GA, within 24 h of sample collection, for further processing.
FDA‑EUA approved assay for the detection of SARS‑CoV‑2 (SARS‑specific assay). The assay

is based on nucleic acid extraction followed by TaqMan-based RT-PCR assay to conduct in vitro transcription
of SARS-CoV-2 RNA, DNA amplification, and fluorescence detection (FDA-EUA assay by PerkinElmer Inc.
Waltham, USA). The assay targets specific genomic regions of the SARS-CoV-2: nucleocapsid (N) gene and
ORF1ab. The TaqMan probes for the two amplicons are labeled with FAM and ROX fluorescent dyes, respectively, to generate target-specific signals. The assay includes an RNA internal control (IC, bacteriophage MS2) to
monitor the processes from nucleic acid extraction to fluorescence detection. The IC probe is labeled with VIC
fluorescent dye to differentiate its fluorescent signal from SARS-CoV-2 targets. The samples were resulted as
positive or negative based on the Ct values specified by the manufacturer (Supplementary file 1). For a detailed
method, please refer to Sahajpal, NS, et al.6.
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Parameters

Total positive

Positive rate (%)

Saliva sample (both assays)

174/1019

17

Saliva (SARS-specific assay)

154/174

88.5

Saliva (multiplex assay)

160/174

91.9

Concordance

140/174

80.4

Table 1.  The overall and assay specific detection rate (%) and concordance data between two assays for saliva
samples.

PKamp assay for the detection of SARS‑CoV‑2, influenza A and B viruses (Multiplex
assay). The PKamp Respiratory SARS-CoV-2 RT-PCR Panel assay (PerkinElmer Inc. Waltham, USA) is a

real-time reverse transcription-polymerase chain reaction (RT -PCR) multiplexed test intended for the simultaneous qualitative detection and differentiation of SARS-CoV-2, influenza A, influenza B, and respiratory syncytial virus (RSV). The oligonucleotide primers and probes for the detection of SARS-CoV-2 include the virus
nucleocapsid (N) gene and ORF1ab gene. The primers and probes for the detection of influenza A and RSV
target regions of matrix protein. The primers and probes for the detection of influenza B target the regions of the
nuclear export protein (NEP) and nonstructural protein 1 (NS1) genes. An additional primer/probe set to detect
the endogenous control targets the RNase P gene and is included in the test. Qualitative assessment is based on
fluorescence detections with TaqMan probes labeled as SARS-CoV-2 (FAM), influenza A (ROX), influenza B
(Cy5), Respiratory syncytial virus (Cy5.5), and RNase P (HEX/VIC). The protocol for extraction and RT-PCR
was described previously7. The samples were resulted as positive or negative based on the Ct values specified by
the manufacturer (Supplementary file 1).

Limit of detection studies. The limit of detection (LoD) studies were conducted as per the FDA guidelines
(https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizat
ions-medical-devices/vitro-diagnostics-euas). Briefly, SARS-CoV-2 reference control material (SARS-CoV-2:
SeraCare (Mat. No. 0505-0159; influenza A and B: SeraCare (Mat. No. 0515-0001) was spiked into the negative
saliva and NPS samples to serve as positive samples at 540 copies/ml, 180 copies/ml, 60 copies/ml and 20 copies/
ml concentrations. The lowest concentration detected in all three triplicates was determined as the preliminary
LoD. To confirm the LoD, 20 replicates of preliminary LoD were analyzed and deemed as confirmed if at least
19/20 replicates were detected.
Data analysis. Data were analyzed for descriptive statistics and presented as a number (%) for categorical
variables and mean ± standard deviation (SD) for continuous variables. Ct values were compared using Paired
T-test.

Results

Clinical performance: saliva samples. Of the 1019 saliva samples, 17.0% (174/1019) tested positive for

SARS-CoV-2 using either assay. The detection rate for SARS-CoV-2 was higher with multiplex assay compared
to SARS-specific assay [91.9% (160/174) vs. 87.9% (153/174)], respectively. The concordance for positive results
between the two tests was 80.4% (140/174) (Table 1). The Ct values for SARS-CoV-2 were comparable between
the two assays (SARS-CoV-2: 29.2 ± 7.2 vs. N: 29.8 ± 6.4, ORF1ab: 28.0 ± 7.1), whereas the Ct values of housekeeping gene was significantly lower with multiplex assay compared to SARS-specific assay [RNaseP: 20.6 ± 2.05
vs. IC: 32.5 ± 2.0 (p < 0.001)], respectively (Fig. 2). Further, the number of tests resulting as invalid was significantly less with the multiplex assay compared to the SARS-specific assay [1.7% (18/1019) vs. 5.6% (58/1019)
(p < 0.001)]. No samples were positive for either influenza A or B.

Clinical performance: NPS samples. Of the 392 saliva samples, 10.4% (41/392) tested positive for SARSCoV-2 using either assay. The detection rate for SARS-CoV-2 was higher with our multiplex assay compared
to the SARS-specific assay [97.5% (40/41) vs. 95.1% (39/41)], respectively. The concordance for positive results
between the two tests was 92.6% (38/41) (Table 2). The Ct values for SARS-CoV-2 were comparable between the
two assays (SARS-CoV-2: 30.8 ± 8.8 vs. N: 31.3 ± 8.6, ORF1ab: 28.8 ± 8.6), whereas the Ct values of housekeeping
gene was significantly lower with multiplex assay compared to SARS-specific assay [RNaseP: 23.1 ± 1.77 vs. IC:
31.3 ± 1.5 (p < 0.001)], respectively (Fig. 3). No samples were positive for either influenza A or B.
Limit of detection studies: saliva samples. In the preliminary LoD study using saliva samples, all rep-

licates were detected at 60, 180, and 540 copies/ml for SARS-CoV-2 and the LoD was determined at 60 copies/
ml, with 20/20 replicates being detected. The preliminary LoD evaluation for influenza A and B identified all
replicates at the four concentrations for influenza B, whereas all replicates at 180 and 540 copies/ml were positive for influenza B. The LoD was established at 180 copies/ml for both influenza A, and B viruses, with 20/20
replicates being detected (Table 3).

Limit of detection studies: NPS samples. In the preliminary LoD study using NPS samples, all replicates at the four tested concentrations (20, 60, 180, and 540 copies/ml) were detected for SARS-CoV-2, and the
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Figure 2.  Plot demonstrating the Ct values of N and ORF1ab genes in SARS-specific assay compared to SARSCoV-2 in the multiplex assay. Comparison of Ct values of housekeeping genes IC and Rnase P in SARS-specific
and Multiplex assay, respectively, for saliva samples.

Parameters

Total positive

Positive rate (%)

NPS sample (both assays)

41/392

10.4

NPS (SARS-specific assay)

39/41

95.1

NPS (multiplex assay)

40/41

97.5

Concordance

38/41

92.6

Table 2.  The overall and assay specific detection rate (%) and concordance data between two assays for NPS
samples.

Figure 3.  Plot demonstrating the Ct values of N and ORF1ab genes in SARS-specific assay compared to SARSCoV-2 in the multiplex assay. Comparison of Ct values of housekeeping genes IC and Rnase P in SARS-specific
and Multiplex assay, respectively, for NPS samples.

LoD was determined at 60 copies/ml, with 20/20 replicates being detected. The preliminary LoD evaluation for
influenza A and B identified all replicated at the four concentrations for influenza B, whereas all replicates at 180
and 540 copies/ml were detected for influenza B. The LoD was established at 180 copies/ml for both influenza A,
and B viruses, with 20/20 replicates being detected (Table 4).
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Preliminary LoD study

SARS-specific assay

Concentrations

SARS-CoV-2N gene (Ct/
replicates)

SARS-CoV-2 ORF1ab gene
(Ct/replicates)

SARS-CoV-2 (Ct/
replicates)

Multiplex assay
Influenza A (Ct/replicates)

Influenza B (Ct/replicates)

20 copies/ml

36.7 ± 0.6

35.1 ± 1.3

37.0 ± 0.87 (2/3)

_ (0/3)

34.9 ± 1.29 (3/3)

60 copies/ml

33.6 ± 0.15 (3/3)

33.7 ± 0.4 (3/3)

34.7 ± 0.52 (3/3)

37.1 (1/3)

34.6 ± 0.61 (3/3)

180 copies/ml

32.7 ± 0.19 (3/3)

32.6 ± 0.2 (3/3)

33.2 ± 0.22 (3/3)

35.7 ± 0.88 (3/3)

32.3 ± 0.57 (3/3)

540 copie/ml

_

_

31.6 ± 0.21 (3/3)

34.5 ± 1.24 (3/3)

31.3 ± 0.55 (3/3)

LoD Confirmation

20 copies/ml: 20/20 replicates detected

20 copies/ml: 20/20 replicates detected

60 copies/ml: 20/20 replicates detected

180 copies/ml: 20/20 replicates detected

180 copies/ml: 20/20 replicates detected

Table 3.  Limit of detection for SARS-CoV-2, influenza A and B viruses for saliva samples with multiplex assay
and for SARS-CoV-2 with SARS-specific assay.

Preliminary LoD study

SARS-specific assay

Concentrations

SARS-CoV-2N gene (Ct/
replicates)

SARS-CoV-2 ORF1ab gene
(Ct/replicates)

SARS-CoV-2 (Ct/
replicates)

Multiplex assay
Influenza A (Ct/replicates)

Influenza B (Ct/replicates)

20 copies/ml

35.6 ± 0.4

35.5 ± 1.1

36.2 ± 0.94 (3/3)

_ (0/3)

35.0 ± 0.81 (3/3)

60 copies/ml

33.2 ± 0.23 (3/3)

33.1 ± 0.8 (3/3)

34.4 ± 0.79 (3/3)

_ (0/3)

33.6 ± 0.61 (3/3)

180 copies/ml

31.9 ± 0.4 (3/3)

31.8 ± 0.1 (3/3)

32.8 ± 0.78 (3/3)

35.3 ± 0.54 (3/3)

32.0 ± 0.59 (3/3)

540 copie/ml

_

_

32.1 ± 0.72 (3/3)

33.9 ± 0.73 (3/3)

30.7 ± 0.04 (3/3)

LoD Confirmation

20 copies/ml: 20/20 replicates detected

20 copies/ml: 20/20 replicates detected

60 copies/ml: 20/20 replicates detected

180 copies/ml: 20/20 replicates detected

180 copies/ml: 20/20 replicates detected

Table 4.  Limit of detection for SARS-CoV-2, influenza A and B viruses for NPS samples.

Discussion

This undocumented health loss due to seasonal influenza viruses has posed severe public health deficiencies, both
at a clinical and epidemiological level8–10. Further, poorly documented co-infections in patients with COVID-19
continue to amplify the morbidity and mortality associated with the p
 andemic4,11. In an attempt to address these
clinical and technical challenges, we propose a simplified protocol for the detection of SARS-CoV-2 along with
common co-infections. We have optimized and validated a highly sensitive, RT-PCR based multiplex assay for
detecting SARS-CoV-2, influenza A, and B viruses in a single test, using the same workflow, instruments, sample types, supplies, and laboratory personnel needed for the testing of SARS-CoV-2 virus (Fig. 1). The clinical
evaluation of 1411 specimens that included 1019 saliva samples and 392 NPS samples demonstrated comparable
performance of the multiplex assay to the SARS-specific FDA-EUA assay. Of the 1019 saliva samples evaluated
with both assays, the detection rate was higher with the proposed multiplex assay compared to the SARS-specific
assay (91.9% (160/174) vs. 87.9% (153/174). Ct values for SARS-CoV-2 with the multiplex assay were comparable
to N and ORF1ab genes with the SARS-specific assay. The marginally higher performance of the multiplex assay
compared to the SARS-specific assay might be attributed to the fact that in the multiplex assay, the amplification
from two regions of the SARS-CoV-2 genome (N and ORF1ab genes) are detected with a single dye (FAM) for
fluorescence detection. Thus, very weak positive samples that do not amplify sufficiently for the respective targets
individually (N: FAM, ORF1ab: ROX) in the SARS-specific assay are being amplified to cross the threshold collectively in the multiplex assay [SARS-CoV-2 (N, ORF1ab): FAM). The concordance between the two assays was
found to be 80.4% (140/174). Upon manual inspection of the Ct values, it was found that the discrepant results
between the assays emerged for samples that show low viral loads with high Ct values, and only one gene detected
(N or ORF1ab) with the SARS-specific assay. The findings were similar with NPS samples, with a slightly higher
detection rate with multiplex assay compared to SARS-specific assay [97.5% (40/41) vs. 95.1% (39/41)], with a
concordance of 92.6% (38/41) between the two assays. The Ct values for SARS-CoV-2 with the multiplex assay
were comparable to N and ORF1ab gene with the SARS-specific assay. Further, the LoD studies performed with
the SeraCare reference material demonstrated high sensitivity of the assay with LoD of 60 copies/ml for SARSCoV-2 and 180 copies/ml for influenza A and B viruses, for both saliva and NPS samples. Notably, no samples
resulted positive for influenza viruses A and B in this study. These results are in alignment with the prevalence
of flu in this state, as reported by the Georgia Department of Public Health. The baseline levels were reported as
0–3%, with an incidence of 0.6% in the second week of December 2020 (https://dph.georgia.gov/epidemiology/
influenza/flu-activity-georgia). Recently, in another single-center evaluation study, the LoD for SARS-CoV-2,
influenza A and B were reported to be 5 copies/reaction, but the LoD was not validated as per FDA guidelines,
and remains to be validated12.
We have previously discussed saliva samples that resulted as inconclusive and have argued that the rate of
these invalid results would decrease with assays that include RNaseP gene as a housekeeping control7,13. Herein,
the number of invalids significantly decreased with the multiplex assay compared to the SARS-specific assay
[1.7% (18/1019) vs. 5.6% (58/1019): p < 0.001], and Ct values for the housekeeping gene was significantly lower
(p < 0.001) with the multiplex assay compared to the SARS-specific assay. The RNase P gene is abundant in both
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the NPS and saliva samples, leading to a definitive result, whereas the addition of an external control (5 µl IC in
SARS-specific assay) might be difficult to extract in complex samples contributing to inconclusive results. It is
recommended that inconclusive samples be re-processed, and if the results still remain inconclusive, then patients
need to be re-tested on a fresh sample. A major advantage of this multiplex assay has been that it did not cause
any significant workflow changes in our laboratory. Existing platforms and even procedures remained essentially
the same as those in use for the last eight months for COVID-19 testing. The only change was in the PCR master
mix composition, which does not cause any change in workflow or TAT. The TAT with SARS-specific assay has
been ~ 14 h for reporting ~ 800 samples/day, and the TAT to report results with the multiplex assay was found to
be similar as assessed by an independent, blinded protocol.
However, the study is limited by the fact that none of our clinical samples were known positive for influenza
A and B viruses. To address this limitation, we obtained the SeraCare reference material for influenza A and B
viruses. We performed the LoD studies by spiking saliva and NPS samples to validate the assay for the detection
of influenza viruses. The second limitation was that Respiratory Syncytial Virus (RSV) was not validated in this
study as the RT-PCR instruments available in the laboratory do not have the channel on which the dye for RSV
detection was labeled. The manufacturers have appropriately provided the procedure for RT-PCR master mix
preparation, where, TE (Tris-EDTA) was added instead of RSV probes in the solution. The laboratories that have
instruments that can detect RSV can easily include the detection of RSV in addition to SARS-CoV-2, influenza
A, and B viruses. The third limitation was that it would have been ideal to sequence the non-concordant samples between the assays to resolve the discrepant results. However, due to exhaustion of the sample, additional
experiments could not be performed. Nonetheless, despite these limitations, this study presents a significant and
clinically validated assay that can be implemented for testing of SARS-CoV-2, influenza A and B viruses, using
NPS and saliva samples for population screening.
Received: 3 June 2021; Accepted: 19 January 2022
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